International Standard for the Protection of Privacy and Personal Information : the World Anti-Doping Code / World Anti-Doping Agency (WADA). - Montreal : WADA, 2008. - (International Standard for the Protection of Privacy and Personal Information (ISPPPI) version 2.0, in effect on 1 June 2009)

The International Standard for the Protection of Privacy and Personal Information was first adopted and approved by the World Anti-Doping Agency Executive Committee on 9 May 2009. The enclosed represents version 2.0 which becomes effective as of 1 June 2009.

The purpose of the International Standard for the Protection of Privacy and Personal Information is to ensure that Anti-Doping Organizations apply appropriate, sufficient and effective privacy protections to the Personal Information they Process when conducting anti-doping programs, in recognition of the fact that Personal Information gathered in the anti-doping context can impinge upon and implicate the privacy rights and interests of persons involved in and associated with organized sport.

The Code, in particular, requires Athletes and Athlete Support Personnel to furnish a significant amount of Personal Information to Anti-Doping Organizations. As a result, it is essential that Anti-Doping Organizations appropriately protect the Personal Information that they collect both to meet legal standards and to ensure the continued confidence and trust of those who participate in organized sport.

The Code recognizes and affirms the importance of ensuring that the privacy interests of persons participating in anti-doping programs based on the Code are fully respected. In support of this commitment, this International Standard provides mandatory rules and standards relating to the protection of Personal Information by Anti-Doping Organizations.

Therapeutic Use Exemptions : the World Anti-Doping Code International Standard / World Anti-Doping Agency (WADA). - Montreal : WADA, 2010. - (International Standard for Therapeutic Use Exemptions (ISTUE) version 5.0, effective on 1 January 2011)

The International Standard for Therapeutic Use Exemptions was first adopted in 2004 and became effective in 2005. The enclosed represents version 5.0 that incorporates revisions to the International Standard for Therapeutic Use Exemptions that were approved by the World Anti-Doping Agency Executive Committee on 18 September 2010. The revised International Standard for Therapeutic Use Exemptions is effective as of 1 January 2011.

The purpose of the International Standard for Therapeutic Use Exemptions is to ensure that the process of granting therapeutic use exemptions is harmonized across sports and countries.

The Code permits Athletes to apply for therapeutic use exemptions (TUE) i.e. permission to use, for therapeutic purposes, substances or methods contained in the List of Prohibited Substances or Methods where Use would otherwise be prohibited.

The International Standard for TUE includes criteria for granting a TUE, confidentiality of information, the formation of Therapeutic Use Exemptions Committees and the TUE application process.

This Standard applies to all Athletes as defined by and subject to the Code i.e. able-bodied Athletes and Athletes with disabilities.

Facts
The French Athletics Federation (Fédération Française d'Athlétisme, FFA) charges respondent M15 for a violation of the Anti-Doping Rules. During an athletics event on September 25, 2010, a sample was taken for doping test purposes. The analysis of the sample showed the presence of prednisone and prednisolone. Prednisone and prednisolone are prohibited substance according the World Anti-Doping Agency (WADA) prohibited list, they are regarded as specified substances.

History
The respondent used medication against angina which caused the positive test.

Decision.
1. The sanction is a period of ineligibility of six months in which respondent can't take part in competition or manifestations organized or authorized by the FFA.
2. All the results obtained on September 25, 2010, are cancelled. Medals, points and prizes are withdrawn.
3. The decision will start on the date of notification.
4. The decision will be published and sent to the parties involved.

Facts
The French Federation of Weightlifting, Fitness, Powerlifting and Bodybuilding (Fédération Française d'Halterophilie, Musculation, Force Athlétique et Culturisme, FFHMFAC) charges respondent M14 for a violation of the Anti-Doping Rules. During a weightlifting event on April 17, 2010, a sample was taken for doping test purposes. The analysis of the sample showed the presence of furosemide, a metabolite of nandrolone, 3α-hydroxy-5α-androstan-17-one, a metabolite of mesterolone, testosterone on epitestosterone in an abnormal high level (spectro analysis shows exogenous metabolites of testosterone) and metabolites of stanozolol . These substances are prohibited according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent declared that the positive test derived from supplements he used, ordered by internet, he had used these, during training, from the end of November 2009 till the date of the doping test.

Decision
1. The sanction is a period of ineligibility of four years in which respondent can't take part in competition or manifestations organized or authorized by the FFHMFAC which was pronounced by the decision of the disciplinary committee of the FFHMFAC on August 3, 2010, and now extended to the other French sport federations.
2. The decision starts on the date of notification.
5. The decision will be published and sent to the parties involved.

THE 2010 MONITORING PROGRAM*

The following substances are placed on the 2010 Monitoring Program:

1. Stimulants:

In-Competition Only: Bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradrol, pseudoephedrine (< 150 micrograms per milliliter), synephrine.

2. Narcotics:

In-Competition Only: Morphine/codeine ratio.

* The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”

THE 2009 MONITORING PROGRAM*

The following substances are placed on the 2009 Monitoring Program:

1. Stimulants:

In-Competition Only: Bupropion, caffeine, phenylephrine,
phenylpropanolamine, pipradrol, pseudoephedrine, synephrine.

2. Narcotics:

In-Competition Only: Morphine/codeine ratio.

* The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”

WADA appealed the FILA Sport Judge decision of 7 September 2009 with the FILA Appeal Commission in the case of the anti-doping rule violation of the Bulgarian Athlete Bozhidar Boyadzhiev.

The Appeal Commission concludes that the Athlete had no intention to enhance his sport performance and his only fault was he didn’t apply for a TUE. Therefore the FILA Appeal Commission decides to give the Athlete a reprimand.

THE 2008 MONITORING PROGRAM*

The following substances are placed on the 2008 Monitoring Program:

1. Stimulants:

a) In-Competition Only: Bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradrol, pseudoephedrine, synephrine.

b) Out-of competition: Adrafinil, adrenaline, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, clobenzorex, cocaine, cyclazodone, dimethylamphetamine, etilamphetamine, etilefrine, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, methylphenidate, modafinil, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phentermine, 4-phenylpiracetam (carphedon), prolintane, strychnine.

2. Narcotics:

In-Competition Only: Morphine/codeine ratio

* The WADA Code (4.5) states: “WADA, in consultation with other Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”

Facts
The French Federation of Weightlifting, Fitness, Powerlifting and Bodybuilding (Fédération Française d'Halterophilie, Musculation, Force Athlétique et Culturisme, FFHMFAC) charges respondent M13 for a violation of the Anti-Doping Rules. During a weightlifting event on April 17, 2010, a sample was taken for doping test purposes. The analysis of the sample showed the presence of carenone, tamoxifen, trenbolone, clenbuterol, metabolites of stanozolol and testosterone on epitestosterone in an abnormal high level (spectro analysis shows exogenous metabolites of testosterone). These substances are prohibited according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent declares he had used supplements to level with his competitors.

Decision
1. The sanction is a period of ineligibility of four years in which respondent can't take part in competition or manifestations organized or authorized by the FFHMFAC which was pronounced by the decision of the disciplinary committee of the FFHMFAC on August 3, 2010, and now extended to the other French sport federations.
2. The decision starts on the date of notification.
5. The decision will be published and sent to the parties involved.

On 17 September 2010 the FILA Sport Judge imposed a 12 month period of ineligibility on the Serbian Athlete Radomir Petkovic after is sample tested positive for the prohibited substance methandienone.
Hereafter WADA appealed the FILA decision of 17 September 2010 with the FILA Appeal Commission.

The Athlete stated that he suffered from a headache and his mother was at fault due she gave him his father’s medication instead of a supplement to treat his headache which she kept together at one place.

The Appeal Commission concludes that the Athlete acted negligently and rejects his statement.
Therefore the FILA Appeal Commission decides to set aside the decision of the FILA Sport Judge and to impose a 2 year period of ineligibility on the Athlete, starting on the date of the sample collection, i.e. 29 May 2010.